Toremifene and Pacritinib: Interaction Details
- Toremifene
- Fareston
- Pacritinib
- Vonjo
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Toremifene and Pacritinib interaction:
What Happens When You Take Toremifene With Pacritinib
What can happen when they are taken together (rated Major)
An increased risk of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Pacritinib should not be given together with any drug that is known to prolong the . Using such drugs at the same time may add to the QTc-prolonging effect of pacritinib and raise the risk of cardiac .
Pacritinib should also be avoided in patients whose baseline QTc is above 480 msec. Pacritinib should be held if the prolongs beyond 500 msec or rises by more than 60 msec over baseline.
Should the QTc return to 480 msec or less, or to baseline, within 1 week, pacritinib can be restarted at the same dose. If resolution takes longer than 1 week, pacritinib should be restarted at a reduced dose. When cannot be avoided, should be corrected before and throughout pacritinib treatment, and QTc prolongation should be managed through interruption of pacritinib and management of electrolytes.1
The Toremifene and Pacritinib Interaction, Explained
Both toremifene (a breast cancer hormone therapy) and pacritinib (a medicine for myelofibrosis) can affect the heart's electrical rhythm. Each can lengthen what doctors call the . Taking them together may add up, which could raise the chance of a dangerous irregular heartbeat. This concern is based on how the drugs work rather than on reports of harm in patients.
If you take both, tell your care team about any fainting, dizziness, or racing or fluttering heartbeat. Do not stop either medicine on your own. Your team can check your heart rhythm and blood salts (like potassium) and tailor your treatment to keep you safe.
() between toremifene, a known QT-prolonging SERM, and pacritinib, which also prolongs . Evidence is theoretical; onset unspecified. Increased risk of /.
- Labeling advises avoiding pacritinib with QT-prolonging drugs and in patients with baseline QTc >480 msec.
- Hold pacritinib if QTc >500 msec or increase >60 msec from baseline.
- If QTc returns to ≤480 msec or baseline within 1 week, resume at the same dose; if >1 week, resume at a reduced dose.
- If is unavoidable, correct before and during therapy, monitor , and manage with interruption and electrolyte management.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Toremifene and Pacritinib Interact
The likely mechanism
How to Manage the Toremifene and Pacritinib Interaction
The usual approach is to avoid using these two together when possible. If your team decides you need both, they can manage the risk carefully.
- Keep taking both medicines as prescribed unless your care team tells you otherwise.
- Your team may check your heart rhythm () and your potassium levels before and during treatment, and correct low potassium.
- If your heart rhythm changes too much, pacritinib may be paused and later restarted, sometimes at a lower dose that your team individualizes.
- Tell your pharmacist or doctor about fainting, dizziness, or a pounding or irregular heartbeat, and about every other medicine you take.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Toremifene or Pacritinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Toremifene and Pacritinib: Common Questions
How serious is the Toremifene and Pacritinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Toremifene and Pacritinib interaction managed?
The usual approach is to avoid using these two together when possible. If your team decides you need both, they can manage the risk carefully. Keep taking both medicines as prescribed unless your care team tells you otherwise. Your team may check your heart rhythm () and your potassium levels before and during treatment, and correct low potassium. If your heart rhythm changes too much, pacritin… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Toremifene and Pacritinib Interaction
Ask in your own words about taking Toremifene and Pacritinib together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: VONJO(R) oral capsules, pacritinib oral capsules. CTI BioPharma Corp (per FDA), Seattle, WA, 2024. DailyMed
Other Serious Interactions of Toremifene and Pacritinib
Also serious with Toremifene
- Ketoconazole TopicalContraindicated
- DronedaroneContraindicated
- KetoconazoleContraindicated
- LevoketoconazoleContraindicated
Also serious with Pacritinib
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Pacritinib
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- American HelleboreMajor
- ArsenicMajor
- CesiumMajor
- EphedraMajor
- Sida CordifoliaMajor
- + 155 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.